BAY-899 | BAY-899 : Allosteric Antagonist of LHCGR
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
LHCGR
    • IC50:185 nM
    Allosteric
    1 uM

    Selectivity

    In Vitro Selectivity Assessment
    Selectivity Assessment Description:
    No activity on FSHR, TSHR. (hTSH antagonism IC50 = 24 µM; hFSH antagonism IC50 > 16 µM) Clean in com ...

    Potency
    Cellular
    In Vitro

    LHCGR

    Mode of Action: Allosteric

    Structure-Activity-Relationship data available? Yes

    DOI Reference: 10.1021/acs.jmedchem.9b01382

    In Vivo Validations

    Rat
    Dose: 2 mg/Kg
    Route of delivery: Oral
    Plasma half life: 12 h
    Cmax: 0.24 Kg/L
    Tmax: 24 h
    Area Under the Curve:: 7.8 Kg*h/L
    Bioavailability: 83 %

    DOI Reference: 10.1021/acs.jmedchem.9b01382

    Dose: 0.5 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 11 h
    Systemic clearance: 0.11 L/h/Kg
    Cmax: 0.97 Kg/L
    Tmax: 0.0 h
    Area Under the Curve:: 9.4 kg*h/L
    Volume of Distribution at Steady-State: 1.8 L/Kg

    DOI Reference: 10.1021/acs.jmedchem.9b01382

    Negative Control Compounds

    BAY-897
    Notes: BAY-897 is inactive on human LHCGR (IC50 > 16 µM) and FSHR (IC50 > 16 µM). Closest hits in the GPCR scan are TMEM97 (Ki = 675.62 nM) and HTR2C (Ki = 1082.93 nM).

    Chemical Information

    Molecular Formula C25H19F2N5O2
    SMILEs O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1
    InChI InChI=1S/C25H19F2N5O2/c26-17-5-3-16(4-6-17)23-21-2-1-12-28-22(21)11-13-32(23)25(33)31-19-14-29-24(30-15-19)34-20-9-7-18(27)8-10-20/h1-10,12,14-15,23H,11,13H2,(H,31,33)/t23-/m0/s1
    Molecular weight 459.15 Da
    AlogP 5.121700000000003
    HBond acceptors 7
    HBond donors 1
    Atoms 53

    Vendors

    Note: This is not an exhaustive list and does not indicate endorsement by the portal.

    Expert Reviews


    No SERP comments found for BAY-899

    Probe BAY-899 is in the process of SERP review.

    Please continue to check back for new reviews and commentary.